|
1）Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185: 881-6
|
|
|
|
2）森本耕三．日本の非結核性抗酸菌症死亡に関する統計的分析．結核．2011; 86: 547-52
|
|
|
|
|
3）Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013; 187: 197-205
|
|
|
|
|
|
4）Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013; 68: 256-62
|
|
|
|
|
|
5）渡辺 彰，鈴木克洋，秋山也寸史，他．肺非結核性抗酸菌症化学療法に関する見解 2012年改訂．結核．2012; 87: 83-6
|
|
|
|
|
|
6）van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012; 186: 559-65
|
|
|
|
|
|
7）Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014; 11: 23-9
|
|
|
|
|
|
8）van Ingen J, Ferro BE, Hoefsloot W, et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther. 2013; 11: 1065-77
|
|
|
|
|
|
9）Hayashi M, Takayanagi N, Kanauchi T, et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012; 185: 575-83
|
|
|
|
|
|
10）Kikuchi T, Kobashi Y, Hirano T, et al. Mycobacterium avium genotype is associated with the therapeutic response to lung infection. Clin Microbiol Infect. 2014; 20: 256-62
|
|
|
|
|